Marshall Wace LLP Sells 579,976 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Marshall Wace LLP cut its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 92.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 48,911 shares of the specialty pharmaceutical company's stock after selling 579,976 shares during the quarter. Marshall Wace LLP owned about 0.12% of KalVista Pharmaceuticals worth $576,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of KALV. Price T Rowe Associates Inc. MD grew its holdings in shares of KalVista Pharmaceuticals by 4.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 22,142 shares of the specialty pharmaceutical company's stock worth $263,000 after buying an additional 944 shares in the last quarter. ClariVest Asset Management LLC raised its holdings in shares of KalVista Pharmaceuticals by 2.8% in the second quarter. ClariVest Asset Management LLC now owns 57,096 shares of the specialty pharmaceutical company's stock valued at $673,000 after purchasing an additional 1,535 shares during the last quarter. Nicholas Investment Partners LP raised its holdings in shares of KalVista Pharmaceuticals by 0.9% in the second quarter. Nicholas Investment Partners LP now owns 184,358 shares of the specialty pharmaceutical company's stock valued at $2,172,000 after purchasing an additional 1,714 shares during the last quarter. nVerses Capital LLC bought a new stake in shares of KalVista Pharmaceuticals in the second quarter worth $25,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in KalVista Pharmaceuticals by 101.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 8,024 shares of the specialty pharmaceutical company's stock worth $95,000 after purchasing an additional 4,043 shares during the last quarter.

KalVista Pharmaceuticals Price Performance

KALV stock traded down $0.25 during trading hours on Thursday, reaching $10.99. The stock had a trading volume of 257,782 shares, compared to its average volume of 506,693. The stock has a market capitalization of $463.65 million, a PE ratio of -3.31 and a beta of 0.89. The stock has a 50-day simple moving average of $11.95 and a 200 day simple moving average of $12.06. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $7.21 and a fifty-two week high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last posted its quarterly earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) EPS for the quarter, topping analysts' consensus estimates of ($0.91) by $0.04. On average, sell-side analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.35 EPS for the current fiscal year.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Christopher Yea sold 7,102 shares of the firm's stock in a transaction on Monday, August 19th. The stock was sold at an average price of $12.01, for a total transaction of $85,295.02. Following the completion of the sale, the insider now owns 84,467 shares of the company's stock, valued at $1,014,448.67. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other KalVista Pharmaceuticals news, insider Christopher Yea sold 7,102 shares of the stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $12.01, for a total value of $85,295.02. Following the transaction, the insider now directly owns 84,467 shares of the company's stock, valued at $1,014,448.67. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Benjamin L. Palleiko sold 14,215 shares of the firm's stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $12.01, for a total transaction of $170,722.15. Following the sale, the chief executive officer now owns 242,527 shares of the company's stock, valued at $2,912,749.27. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 30,804 shares of company stock worth $372,112. 12.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

KALV has been the topic of several recent research reports. HC Wainwright reissued a "buy" rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Monday. Cantor Fitzgerald reiterated an "overweight" rating on shares of KalVista Pharmaceuticals in a report on Monday, September 9th. Finally, Needham & Company LLC restated a "buy" rating and issued a $32.00 price target on shares of KalVista Pharmaceuticals in a research note on Friday, September 6th.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.